To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

Shahid Beheshti University of Medical Sciences40 enrolled

Overview

Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Resistant Cystoid Macular Edema

Interventions

Intravitreal injection of TriamcinoloneDRUG

4 mg of Triamcinolone

Intravitreal injection of AvastinDRUG

Injection of 1.25 mg of Avastin and

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Uveitic CME * Uveitic CME refractory to routine treatment * Vision better than 5/200 and worse than 20/50 Exclusion Criteria: * Mono- Ocular patients * History of vitrectomy * Glaucoma or ocular hypertension * History of other retinal disease that can cause macular edema * Pregnancy * Significant media opacity * Vision better than 20/50

Locations (1)

Masoud Soheilian , MD

Tehran, Tehran Province, Iran

Outcomes

Primary Outcomes

Resorbed CME in OCT

Time frame: every 3 month

Resorbed CME in clinical examination

Time frame: Every 3 month

Secondary Outcomes

need to retreatment

Time frame: when ever needed

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.